SEC Form 4 · accession 0001447348-15-000016
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Israel
Officer — Executive Vice President, Medi
Period of report
Mar 3, 2015
Accepted (ET)
Mar 4, 2015 · 2:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 3, 2015 | M | 5,000 | $4.70 | A | 40,050 | D | |
| Common StockF1,F2 | Mar 3, 2015 | S | 5,000 | $6.49 | D | 35,050 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2,F3 | $4.70 | Mar 3, 2015 | M | 5,000 | D | — | Mar 3, 2024 | Common Stock | 5,000 | 61,000 | D |
Explanation of responses
- F1The Reporting Person is exercising options under this grant in pre-established increments under and in accordance with provisions of a previously established Plan of Sale under Rule 10b5-1, which was established in accordance with the policies and procedures of the Issuer.
- F2This transaction was executed in multiple trades at various price ranges. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The stock options become exercisable in three equal annual installments, commencing one year from the grant date.